Table 1.
Patient characteristics at baseline
| Characteristic | N = 20 |
|---|---|
| Median age (range), y | 51.0 (29‐79) |
| Gender, n (%) | |
| Female | 12 (60.0) |
| Male | 8 (40.0) |
| Race, n (%) | |
| Asiana | 20 (100) |
| WHO PS, n (%) | |
| 0 | 11 (55.0) |
| 1 | 9 (45.0) |
| Smoking history, n (%) | |
| Never smoked | 8 (40.0) |
| Ex‐smoker | 11 (55.0) |
| Current smoker | 1 (5.0) |
| Histology/cytology, n (%) | |
| Adenocarcinoma | 20 (100) |
| Stage at time of study entry, n (%) | |
| Stage IIIB | 1 (5.0) |
| Stage IV | 19 (95.0) |
| Brain metastases, n (%) | 12 (60.0) |
| Prior lines of anticancer regimens, n (%) | |
| 1 | 6 (30.0) |
| 2 | 9 (45.0) |
| 3 | 5 (25.0) |
| Prior radiotherapy, n (%) | |
| Yes | 11 (55.0) |
| No | 9 (45.0) |
| Therapy type at last treatment, n (%) | |
| Chemotherapy | 4 (20.0) |
| Targeted therapyb | 17 (85.0) |
| Prior ALK inhibitor, n (%) | |
| Alectinib only | 16 (80.0) |
| Alectinib and crizotinibc | 4 (20.0) |
| Best response to prior alectinib, n (%) | |
| CR | 3 (15.0) |
| PR | 14 (70.0) |
| SD | 1 (5.0) |
| Unknown | 2 (10.0) |
| Reason for alectinib discontinuation, n (%) | |
| PD | 20 (100) |
| Time since initial diagnosis of primary site to start of ceritinib treatment (months), median (range) | 25.82 (6.5‐137.5) |
ALK, anaplastic lymphoma kinase; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; WHO PS, World Health Organization performance status.
a
One patient was not Japanese.
b
Targeted therapy includes alectinib and bevacizumab. One patient who previously received bevacizumab and chemotherapy as a last regimen was counted in each category.
c
All 4 patients received crizotinib before prior alectinib.